News headlines about Medpace Holdings (NASDAQ:MEDP) have trended somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medpace Holdings earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6828611163457 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities analysts recently weighed in on the stock. Raymond James Financial, Inc. began coverage on Medpace Holdings in a report on Friday, September 29th. They issued a “market perform” rating for the company. KeyCorp reissued a “hold” rating on shares of Medpace Holdings in a report on Tuesday, October 17th. Robert W. Baird reissued a “hold” rating and issued a $32.00 target price on shares of Medpace Holdings in a report on Monday, October 9th. Zacks Investment Research raised Medpace Holdings from a “hold” rating to a “strong-buy” rating and set a $38.00 target price for the company in a report on Saturday, September 9th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $31.00 target price (up previously from $30.00) on shares of Medpace Holdings in a report on Wednesday, August 2nd. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $34.20.
Shares of Medpace Holdings (NASDAQ MEDP) traded up 2.23% on Thursday, reaching $34.85. 102,666 shares of the company traded hands. Medpace Holdings has a 52-week low of $21.76 and a 52-week high of $38.94. The company has a market capitalization of $1.38 billion, a PE ratio of 61.36 and a beta of -0.86. The firm has a 50-day moving average of $32.58 and a 200-day moving average of $29.82.
Medpace Holdings (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.08. Medpace Holdings had a return on equity of 9.32% and a net margin of 5.37%. The company had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $92.71 million. During the same period in the prior year, the company earned $0.45 EPS. Medpace Holdings’s revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts forecast that Medpace Holdings will post $1.43 earnings per share for the current fiscal year.
In other news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $30.27, for a total value of $60,540,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.80% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Medpace Holdings (NASDAQ:MEDP) Receiving Somewhat Favorable News Coverage, Study Finds” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/26/medpace-holdings-medp-receiving-somewhat-positive-press-coverage-analysis-shows.html.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.